Long-term efficacy including clinical NEDA and safety of three-times-weekly dosing regimen of glatiramer acetate: 7-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study

被引：0
|
作者：
Rieckmann, P. [1 ]
Alexander, J. [2 ]
Kadosh, S. [3 ]
Rubinchick, S. [3 ]
Stark, Y. [3 ]
Zivadinov, R. [4 ]
机构：
[1] Med Pk, Loipl, Germany
[2] Teva Pharmaceut, Frazer, PA USA
[3] Teva Pharmaceut, Netanya, Israel
[4] SUNY Buffalo, Buffalo, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P659
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [1] Long-term follow-up of three-times-weekly glatiramer acetate: 7-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Rieckmann, P.
    Alexander, J.
    Kadosh, S.
    Rubinchick, S.
    Stark, Y.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 194 - 194
  • [2] Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Rieckmann, Peter
    Zivadinov, Robert
    Boyko, Alexey
    Selmaj, Krzysztof
    Alexander, Jessica K.
    Kadosh, Shaul
    Rubinchick, Svetlana
    Bernstein-Hanlon, Emily
    Stark, Yafit
    Ashtamker, Natalia
    Davis, Mat D.
    Khan, Omar
    [J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [3] Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
    Khan, Omar
    Rieckmann, Peter
    Boyko, Alexey
    Selmaj, Krzysztof
    Ashtamker, Natalia
    Davis, Mat D.
    Kolodny, Scott
    Zivadinov, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 818 - 829
  • [4] Long-term efficacy, safety, and tolerability of three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 5-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Alexander, Jessica
    Beygi, Hooman
    Feldman, Peter
    Ashtamker, Natalia
    [J]. NEUROLOGY, 2018, 90
  • [5] Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Kolodny, S.
    Davis, M. D.
    Ashtamker, N.
    Steinerman, J. R.
    Zivadinov, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 119 - 120
  • [6] Efficacy and safety of a 3 times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Boyko, A. N.
    Selmaj, K. W.
    Ashtamker, N.
    Davis, M. D.
    Kolodny, S.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 711 - 711
  • [7] Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study.
    Kolodny, S.
    Khan, O.
    Rieckmann, P.
    Davis, M. D.
    Ashtamker, N.
    Steinerman, J. R.
    Zivadinov, R.
    Grinspan, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 417 - 417
  • [8] Twenty-Five Years of Continuous Treatment of Multiple Sclerosis with Glatiramer Acetate: Long-Term Safety Results of the US Open-Label Extension Study
    Ford, Corey
    Barnett-Griness, Ofra
    Alexander, Jessica
    Rubinchick, Svetlana
    Stark, Yafit
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 54 - 54
  • [9] Twenty-seven years of continuous treatment of multiple sclerosis with glatiramer acetate: long-term efficacy results of the US open-label extension study
    Ford, C.
    Cohen, J.
    Goodman, A.
    Lindsey, J.
    Lisak, R.
    Luzzio, C.
    Pruitt, A.
    Rose, J.
    Rus, H.
    Wolinsky, J.
    Alexander, J.
    Kadosh, S.
    Bernstein-Hanlon, E.
    Stark, Y.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 323 - 324
  • [10] Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis
    Johnson, KP
    Brooks, BB
    Ford, CC
    Goodman, AD
    Guarnaccia, JB
    Lisak, RP
    Myers, LW
    Panitch, HS
    Pruitt, AA
    Kachuck, N
    Wolinsky, JS
    [J]. NEUROLOGY, 2002, 58 (07) : A458 - A458
12345